Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.44 USD
-0.56 (-2.43%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $22.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 261 - 280 ( 295 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL as IND for Lead ATTR Candidate Pushed Back into 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Potential Headline Risk with Pending Court Decision, LT Impact Likely Minimal
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
2Q, Continued Progress should help Close Valuation Gap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Transparency on IND Timing for ATTR, Gene Editing Progress in Other Indications
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
YE17 Financials; IND-Enabling Studies to Begin for Lead ATTR Candidate Mid-2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
ASH Presentations Highlight Gene Editing Progress in Hemoglobinopathies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Landmark Achieved with First Crispr/Cas9 Editing in Non- Human Primate Livers
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Updated Mouse Data Shows Long-Term Benefit with Crispr/ Cas9
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D